ArticleEuropean journal of medical research2025
Enoxaparin alleviates preeclampsia by enhancing trophoblast function via the NSUN2-mediated m
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NSUN2-Mediated mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- 5-Methylcytidine RNA Epitranscriptomics in Women's Health and Disease: Mechanisms and Clinical Implications.Cells · 2026Review
- Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivePreeclampsia (PE), a complex multisystem disorder, is a major contributor to maternal and perinatal morbidity and mortality. Enoxaparin, a low-molecular-weight heparin, has shown therapeutic efficacy in preventing various diseases. This study aimed to investigate the role of enoxaparin in PE and clarify its underlying mechanisms.
methodsTrophoblast (HTR-8/SVneo) cell viability, proliferation, migration, and invasion under hypoxia were assessed by Cell Counting Kit-8 (CCK-8), EdU incorporation, wound healing, and Transwell assays. Global RNA m
resultsEnoxaparin enhanced trophoblast proliferation, migration, and invasion under hypoxia. It upregulated the m
conclusionsEnoxaparin mitigated PE progression by upregulating NSUN2, which enhanced PAX3 expression via site-specific m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.